Barasertib (AZD1152-HQPA)

For research use only. Not for use in humans.

目录号:S1147 别名: AZD2811, INH-34 中文名称:巴拉塞替

Barasertib (AZD1152-HQPA) Chemical Structure

CAS No. 722544-51-6

Barasertib (AZD1152-HQPA, AZD2811, INH-34) 是一种高度选择性的Aurora B抑制剂,无细胞试验中IC50为0.37 nM,作用于Aurora B比作用于Aurora A选择性高3700倍左右。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1375.46 现货
RMB 976.12 现货
RMB 3169.53 现货
RMB 5477.43 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Barasertib (AZD1152-HQPA)发表文献85篇:

产品安全说明书

Aurora Kinase抑制剂选择性比较

生物活性

产品描述 Barasertib (AZD1152-HQPA, AZD2811, INH-34) 是一种高度选择性的Aurora B抑制剂,无细胞试验中IC50为0.37 nM,作用于Aurora B比作用于Aurora A选择性高3700倍左右。
靶点
Aurora B [1]
(Cell-free assay)
0.37 nM
体外研究

AZD1152作用于Aurora B比作用于Aurora A选择性高3000多倍,IC50为1.368 μM。AZD1152作用于50种其他丝-苏氨酸和酪氨酸激酶,包括FLT3, JAK2, 和 Abl活性更低。AZD1152 抑制造血恶性细胞增殖,如HL-60, NB4, MOLM13, PALL-1, PALL-2, MV4-11, EOL-1, THP-1, 和K562细胞,IC50为3-40 nM,效果比另一种Aurora激酶抑制剂ZM334739高100多倍,IC50为3-30 μM。AZD1152抑制MOLM13和MV4-11细胞克隆生长,IC50分别为1 nM和2.8 nM,也抑制新分离的抗Imatinib的白血病细胞,IC50 为1-3 nM, 比作用于骨髓单核细胞更有效,IC50>10 nM。AZD1152 诱导携带 4N/8N DNA的细胞累积,随后凋亡,这种作用存在剂量和时间依赖性。 [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LNCaP M{\5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz0VZFWOC13MECgcm0> MoftOFjDqGh? NYDYN415UUN3ME2yOUBvVQ>? NFrRZ3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK3O|Y2QSd-MkWyO|c3PTl:L3G+
LNCaP MV7BdI9xfG:|aYOgRZN{[Xl? NUjDeFdqOC13MECgcm0> MnW4OFjDqGh? M1TaUolv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIghfGi{b4XnbEBk[XOyYYPlMVMhfXC{ZXf1cIF1cW:w NUC2XnIxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c3PTlpPkK1Nlc4PjV7PD;hQi=>
LNCaP M1[xOmZ2dmO2aX;uJGF{e2G7 NIP6XGI2OCCwTR?= M3jYXFQ5KGh? NF3JZlZqdmS3Y3XzJI1q[3KxboXjcIVqKHerdHigZY5mfWenbnnjJI1m[2ijbnnzcS=> NWjzZXlVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|c3PTlpPkK1Nlc4PjV7PD;hQi=>
Ramos MVfGeY5kfGmxbjDBd5NigQ>? NIrGSYg2ODBibl2= NID2UZUxNTd{IHi= M1\kO4lvcGmkaYTzJGF2em:{YTDCJItqdmG|ZR?= NFHWb5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Daudi  M4izSmZ2dmO2aX;uJGF{e2G7 MnXGOVAxKG6P NWXGPGFvOC15MjDo NF3FXoxqdmirYnn0d{BCfXKxcnGgRkBscW6jc3W= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L540 NXjUc45nTnWwY4Tpc44hSXO|YYm= Mnf6OVAxKG6P M3PUclAuPzJiaB?= M{mwRYlvcGmkaYTzJGF2em:{YTDCJItqdmG|ZR?= NED5OI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
BJAJ MlL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLZOVAxKG6P Mk\BNE04OiCq MmjubY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= NILac2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
Ramos NYP6dYFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\3O3NMPTByIH7N MnHtNE04OiCq NFHlcZpqdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5 MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji NHvvOXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jCe|UxOCCwTR?= M3nmZ|AuPzJiaB?= M1P5[IlvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
Daudi  MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX61NFAhdk1? MoPrNE04OiCq Mk\CbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2mpbnnmbYNidnSueR?= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L428 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PZNFUxOCCwTR?= M3PKflAuPzJiaB?= NGfBOZRqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MmqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
KM-H2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzSPIY2ODBibl2= MlP0NE04OiCq M1L1XolvcGmkaYTzJINmdGxiZ4Lve5Rp MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
HDLM-2 Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jzO|UxOCCwTR?= MXKwMVczKGh? NFXFe5NqdmirYnn0d{Bk\WyuIHfyc5d1cA>? Mn3LQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
L450 NUnZW5BLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXy1NFAhdk1? MmnSNE04OiCq Mmm2bY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mlj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
BJAJ NVfRbldLSXCxcITvd4l{KEG|c3H5 NIW3T|c2ODBibl2= NEDWVlcxNTd{IHi= NVTwSnJtcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NX7KXWV2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Ramos NH;lbXBCeG:ydH;zbZMhSXO|YYm= MX21NFAhdk1? NFj6e|UxNTd{IHi= M2exZ4lv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
Raji M1PjR2Fxd3C2b4Ppd{BCe3OjeR?= NHPMe4U2ODBibl2= MUSwMVczKGh? NYWyWppHcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NW\aT5piRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
Daudi  MWTBdI9xfG:|aYOgRZN{[Xl? MVm1NFAhdk1? M1u0cVAuPzJiaB?= M3P4Wolv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHzUOms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
L428 NHjtcGtCeG:ydH;zbZMhSXO|YYm= MYC1NFAhdk1? NXjGOo9mOC15MjDo M4f4dIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NVjjdXlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGzO|E1PDZpPkKxN|cyPDR4PD;hQi=>
KM-H2 M1LtXmFxd3C2b4Ppd{BCe3OjeR?= NWHlSmE{PTByIH7N M2frPFAuPzJiaB?= MUTpcoR2[2W|IHHwc5B1d3OrczDpckBiKHSrbXWt[IVx\W6mZX70JI1idm6nch?= Mki1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF|N{G0OFYoRjJzM{exOFQ3RC:jPh?=
HDLM-2 NYHNNHRiSXCxcITvd4l{KEG|c3H5 MlPEOVAxKG6P M{S5blAuPzJiaB?= NYDxU3ZVcW6mdXPld{BieG:ydH;zbZMhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN5MUS0Okc,OjF|N{G0OFY9N2F-
L450 MlP0RZBweHSxc3nzJGF{e2G7 MoDrOVAxKG6P NFjvWWExNTd{IHi= MknYbY5lfWOnczDhdI9xfG:|aYOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NGHDZlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO3NVQ1Pid-MkGzO|E1PDZ:L3G+
SW620 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrZSVhtTUN3ME2xNOKyOi5zIH7N Mk\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{NEWwPVAoRjJzMkS1NFkxRC:jPh?=
HCT116 MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf6SIxnTUN3ME2xNeKyOy5|IH7N MnvqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF{NEWwPVAoRjJzMkS1NFkxRC:jPh?=
MDA-MB-435 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVewMVExODByIH7N MVKyMVUh\A>? NH\UOoZFVVOR NVK5eoZQUUN3ME2xNlUhdk1? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-468 MmHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\a[5ZIOC1zMECwNEBvVQ>? MWSyMVUh\A>? M37kSWROW09? M1OyNWlEPTB;MUSgcm0> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-231 M3vX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTsdIwxNTFyMECwJI5O MYmyMVUh\A>? MXHEUXNQ MmC2TWM2OD1zMEWgcm0> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
BT474 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGG1eWQxNTFyMECwJI5O NXu0NHFwOi13IHS= MoPNSG1UVw>? NWHvOHlyUUN3ME24JI5O M{jQZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
MDA-MB-361 NVPJNlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWGwMVExODByIH7N NXTjeIlxOi13IHS= NEnqVINFVVOR NIfsc3RKSzVyPUewJI5O MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
HER18 NH3Qc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XROFAuOTByMECgcm0> M{LWRlIuPSCm MnzBSG1UVw>? NEjsUmlKSzVyPUKwJI5O M{XxW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUe1PVI3Lz5{MEG3OVkzPjxxYU6=
HER18 NVz3RXFwSXCxcITvd4l{KEG|c3H5 Mk[3NVAxKG6P NGPCWYcxNzJ2L{S4JIg> MVvEUXNQ NEDBVGxqdmS3Y3XzJIFxd3C2b4Ppd{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIDveIVvfGmjbB?= MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF5NUmyOkc,OjBzN{W5NlY9N2F-
MDA-MB-231 M3\HXWFxd3C2b4Ppd{BCe3OjeR?= M1npd|ExPSCwTR?= M4D3W|AwOjRxNEigbC=> M{HwUmROW09? MVnpcoR2[2W|IHHwc5B1d3OrczDhcoQhemWmdXPld{BkdG:wb3flcolkKHCxdHXueIlidA>? NXLFXYg2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxO|U6OjZpPkKwNVc2QTJ4PD;hQi=>
JHH-1 M2LUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLRNE4{6oDVMUCwNOKhdk1? M{O4b|czKGh? M2XEWWVEPTB;MUeuOOKyOS5yIH7N M1TTXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
JHH-2 MmnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHMWG5MOC5|4pETNVAxOMLibl2= MmfIO|IhcA>? MWnFR|UxRTJzOD6wxtEyOC56IH7N M1f2OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
JHH-4 MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD5bVI{OC5|4pETNVAxOMLibl2= MnO4O|IhcA>? MVfFR|UxRTF3NT62xtEyPi56IH7N M1z5fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-1 NGjEOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4f2RlAvO+LCk{GwNFDDqG6P NGDWVFE4OiCq MVfFR|UxRTJ5LkRCtVUvOCCwTR?= NVnsR5F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
HuH-6 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS3T|E2OC5|4pETNVAxOMLibl2= MmHBO|IhcA>? NWXpeoU2TUN3ME2zMlfDuTBwNjDuUS=> M2GxcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
HuH-7 M3Toe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWwMlPjiJNzMECwxsBvVQ>? NVe5W4tTPzJiaB?= NGmxWoVGSzVyPU[uPOKyOC5|IH7N MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUO5N|UoRjF7OUGzPVM2RC:jPh?=
HLE NFizXGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXrWpNxOC5|4pETNVAxOMLibl2= MkTJO|IhcA>? Mn;sSWM2OD12NT65xtE3NjRibl2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzM{mzOUc,OTl7MUO5N|U9N2F-
HLF NHfXbIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnezNE4{6oDVMUCwNOKhdk1? M1fiRVczKGh? MWLFR|UxRTF{Nj6xxtEyOi5{IH7N M1zLNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUGzPVM2Lz5zOUmxN|k{PTxxYU6=
PLC/PRF/5 NFPhO2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\j[lAvO+LCk{GwNFDDqG6P Mn3EO|IhcA>? MoD1SWM2OD15Nj65xtE6Njlibl2= NW\L[3diRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
SK-Hep1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnCNE4{6oDVMUCwNOKhdk1? NWT1WoxpPzJiaB?= NVfqfWY6TUN3ME2yNU46yrFzLkKgcm0> NX7kRXdCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
Hep3B MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6wNE4{6oDVMUCwNOKhdk1? NFvwc|Y4OiCq MYHFR|UxRTdwNtMxNU4zKG6P NGrOfmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxN|k{PSd-MUm5NVM6OzV:L3G+
HepG2 NUOzdoxST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMlPjiJNzMECwxsBvVQ>? MVu3NkBp MoX2SWM2OD1zND63xtEyNjdibl2= NYixR2xVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVM6OzVpPkG5PVE{QTN3PD;hQi=>
Ramos NVfYNIRiSXCxcITvd4l{KEG|c3H5 M3TXdlI2NzVyL{GwNEBvVQ>? NXf0b3h1PDhiaB?= MV7pcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgZ4xm[X[nZDDmc5JueyCxZjDQRXJRKGGwZDDjZZNx[XOnIEO= M{nVeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEKzNVY5Lz5zOUiyN|E3QDxxYU6=
Daudi  M3S2eWFxd3C2b4Ppd{BCe3OjeR?= Mo\ENlUwPTBxMUCwJI5O MmXYOFghcA>? NF3QSoJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUh[2ynYY\l[EBnd3KvczDv[kBRSVKSIHHu[EBk[XOyYYPlJFM> NI\nRYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUiyN|E3QCd-MUm4NlMyPjh:L3G+
BALM-14 NIP2foJCeG:ydH;zbZMhSXO|YYm= NEnkdVgyOi53L{K1M|UxKG6P MoPIOFghcA>? Ml\3bY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh{M{G2PEc,OTl6MkOxOlg9N2F-
BALM-27 NFnhVI1CeG:ydH;zbZMhSXO|YYm= MVuxNk42NzJ3L{WwJI5O M1z2SVQ5KGh? MnPmbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJINt\WG4ZXSg[o9zdXNib3[gVGFTWCCjbnSgZ4F{eGG|ZTCz MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTh{M{G2PEc,OTl6MkOxOlg9N2F-
NB4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TVflAvODFxMD6xM|Eh|ryP MmDaOFghcA>? M3;tR4lvcGmkaYTzJINmdGxiZ4Lve5RpKHOrZ37p[olk[W62bIm= MlHLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh|Nke0PFQoRjF6M{[3OFg1RC:jPh?=
HeLa NIexN5dHfW6ldHnvckBCe3OjeR?= MkLxNUB2VQ>? NXWy[ZBzOjRiaILz NH7GTGRKdmirYnn0bY9vKG:oIHH1do9z[SCEIHH1eI9xcG:|cHjvdplt[XSrb36gbY4hcHWvYX6gTIVN[SClZXzsd{BifCBzIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6p Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB4OES1OFkoRjJyNki0OVQ6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AURKB / pSer10 Histone H3 / TP53 / CDKN1A / MYCN; 

PubMed: 26497213     


Downstream effects of barasertib-induced AURKB inhibition on histone H3 phosphorylation and TP53 protein levels in IMR5 and SK-N-BE (2c) as indicated after 24h (left) and 48h (right). TP53 and its downstream effector CDKN1A were up-regulated by barasertib䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

p53 / p21 / p-p38 / p38 ; 

PubMed: 24782314     


U2OS cells were treated with 50 nm or 100 nm AZD1152 for 24 h. p21, p38, p-p38, and p53 levels were determined by immunoblotting β-actin served as a loading control.

26497213 24782314
Immunofluorescence
p21 ; 

PubMed: 24782314     


U2OS cells were treated as in H. Levels of p21 were analyzed by immunostaining. DNA was counterstained with Hoechst 33258.

24782314
Growth inhibition assay
Cell viability ; 

PubMed: 26497213     


Dose response curves to barasertib at 72h of incubation normalized to the DMSO control sample (mean ± SD, n = 5). The inset depicts the normalized AUCs of each response curve. 

26497213
体内研究 AZD1152 按25 mg/kg剂量单独处理MOLM13移植瘤,显著抑制肿瘤生长,平均肿瘤体积从1261 mm3 降低到 71 mm3,且平均肿瘤重量从583 mg降低到78 mg, 观察到坏死组织被吞噬细胞浸润。[1]此外, AZD1152 每天按10-150 mg/kg剂量处理多种人类实体移植瘤,包括 结肠癌,乳腺癌,和肺癌,显著抑制肿瘤生长,这种作用存在剂量依赖性。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:[1]
- 合并
  • Cell lines: HL-60, NB4, MOLM13, PALL-2, MV4-11, EOL-1,和 K562
  • Concentrations: 溶于 DMSO, 终浓度为~100 nM
  • Incubation Time: 24或48小时
  • Method: 使用不同浓度AZD1152处理细胞 24或 48小时。通过测量 3H-胸甘摄取(在收集前6小时,加入同位素)而测量细胞增殖,根据剂量-反应曲线计算IC50值。通过流式细胞仪分析细胞周期。通过膜联蛋白V–FITC凋亡检测试剂盒测量细胞凋亡。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 皮下注射MOLM13细胞的雌性免疫缺陷BALB/c裸鼠
  • Dosages: 5 或25 mg/kg
  • Administration: 腹腔注射,每周4次,或每隔一天一次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 102 mg/mL (200.96 mM)
Water Insoluble
Ethanol '3 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+40% PEG 300+2% Tween 80+ddH2O
7mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 507.56
化学式

C26H30FN7O3

CAS号 722544-51-6
储存条件 粉状
溶于溶剂
别名 AZD2811, INH-34

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03217838 Active not recruiting Drug: AZD2811|Drug: Azacitidine|Drug: Venetoclax Acute Myeloid Leukaemia AstraZeneca July 31 2017 Phase 1|Phase 2
NCT02579226 Completed Drug: AZD2811 Advanced Solid Tumours AstraZeneca October 28 2015 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Can you let me know what solvent I can use for Barasertib, cat # S1147, for in vivo use? (IP injection in mice)

  • 回答:

    S1147 Barasertib (AZD1152-HQPA) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30mg/ml as a clear solution. Usually, when prepare the solution, we will add organic solvents first, then add Tween 80, then water. But this compound can not dissolve in 30% PEG400/0.5% Tween80/5% Propylene glycol clearly. After water was added, it became a clear solution.

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

相关Aurora Kinase产品

Tags: 购买Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)供应商 | 采购Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)价格 | Barasertib (AZD1152-HQPA)生产 | 订购Barasertib (AZD1152-HQPA) | Barasertib (AZD1152-HQPA)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID